HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 4237Erstellt: 4. November 2026
Mofezolac
N-22 · Disopain · Mofezolac · Mofezolac, 10 mM in DMSO · 3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid · 3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid · 5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- · 2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid
https://huagongshe.com/de/chemical/4237
Identifikatoren & physikalische Daten
| CAS No. | 78967-07-4 |
|---|
| Summenformel | C19H17NO5 |
|---|
| Durchschnittliche Molmasse | 339,3 g/mol |
|---|
| Monoisotopische Masse | 339,11067264 g/mol |
|---|
| SMILES | COc1ccc(-c2noc(CC(=O)O)c2-c2ccc(OC)cc2)cc1 |
|---|
| InChIKey | DJEIHHYCDCTAAH-UHFFFAOYSA-N |
|---|
| PubChem CID | 4237 |
|---|
| ChEMBL | CHEMBL259972 |
|---|
| ChEBI | CHEBI:31860 |
|---|
| EC No. | 104-920-4 |
|---|
| DTXSID | DTXSID1046716 |
|---|
Chemische & physikalische Eigenschaften
| XLogP | 3,1 |
|---|
| Polarare Oberfläche (TPSA) | 81,8 |
|---|
| H-Brücken-Donoren | 1 |
|---|
| H-Brücken-Akzeptoren | 6 |
|---|
| Frei drehbare Bindungen | 6 |
|---|
| Schwere Atome | 25 |
|---|
| Formalladung | 0 |
|---|
| Komplexität | 430 |
|---|
| Schmelzpunkt | 147.5℃ |
|---|
| Siedepunkt | 527.2±50.0 °C(Predicted) |
|---|
| Dichte | 1.250±0.06 g/cm3(Predicted) |
|---|
| Lagerbedingungen | 2-8°C |
|---|
| Löslichkeit | DMSO: soluble |
|---|
| Aggregatzustand | A solid |
|---|
| pKa (Säurekonstante) | pKa ~3.3(at 25℃) |
|---|
| Farbe | White to off-white |
|---|
Sicherheit & Vorschriften
| Toxizität | LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally275, 321, 378, 342 i.p.612, 545, 572, 510 s.c. (Satoh) |
|---|
Anwendungen & Verwendung
Beschreibung
Mofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in Japan for the treatment of post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent suppression in various writhing models than agents such as ibuprofen, mefenamic acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. The ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of indomethacin and other agents.
